Funding for this research was provided by:
Novo Nordisk A/S
Received: 19 January 2017
Accepted: 10 January 2018
First Online: 18 January 2018
Ethics approval and consent to participate
: The DAWN2 study was conducted in accordance with the relevant national/regional/local guidelines relating to the conduct of non-interventional studies, using the guidelines of the International Chamber of Commerce / European Society for Opinion and Marketing Research, the Council of American Survey Research Organizations, and Good Pharmacoepidemiology Practices (UTN No: U1111–1123-7509; NCT01507116). All participants provided informed consent. The data were used with permission of Novo Nordisk.
: Not applicable
: GN reports no conflict of interest. FP has received funding for travel and accommodation to attend DAWN2 International Publication Planning Committee meetings. His research group received a research grant from Novo Nordisk to conduct statistical analyses and describe results of the DAWN2 study and submit this work for publication.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.